TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26764881

Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial keratoplasty
Number of subjects: 66
Study: 26765643

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 5142

Group type: COMPARATOR
Intervention: Standard anticoagulation therapy
Number of subjects: 5142
Study: 26765645

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (10 mg per day for 10 days)
Number of subjects: 25
Study: 26765812

Group type: EXPERIMENTAL
Intervention: Vitamin B6 restriction for 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation in subjects with chronically low vitamin B6 status
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin B6 deficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical whole body transsulfuration flux
Number of subjects: 0
Study: 26765937

Group type: EXPERIMENTAL
Intervention: Liver transplantation for HIV-positive recipients with MELD ≥ 15
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Liver transplantation for HIV-positive recipients with MELD < 15
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Kidney transplantation for HIV-positive recipients
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Kidney transplantation for HIV-positive recipients (unmatched analysis)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Kidney transplantation for HIV-positive recipients (risk-matched analysis)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Comparison with HIV-negative controls
Number of subjects: 63
Study: 26766736

Group type: EXPERIMENTAL
Intervention: PI3K/AKT/mTOR inhibitors
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Large microRNA cluster on chr19q13.42
Number of subjects: 35

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 35
Study: 26766751

Group type: EXPERIMENTAL
Intervention: EDIPPP outreach and education model
Number of subjects: 337
Study: 26766959

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 26767310

Group type: EXPERIMENTAL
Intervention: Surgery on the lower gastrointestinal tract
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Severity of adhesions in the operative area
Number of subjects: 604
Study: 26767709

Group type: COMPARATOR
Intervention: Pipeline Embolization Device alone
Number of subjects: 793

Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device with concurrent coil embolization
Number of subjects: 793
Study: 26768369

Group type: EXPERIMENTAL
Intervention: Liposomal formulations of amphotericin B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercial amphotericin B lipid products
Number of subjects: 0
Study: 26768570

Group type: EXPERIMENTAL
Intervention: Convalescent plasma and supportive care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 0
Study: 26768772

Group type: EXPERIMENTAL
Intervention: ED-initiated palliative care consultation
Number of subjects: 136

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 136
Study: 26769776

Group type: EXPERIMENTAL
Intervention: Preoperative physical activity level 3 or 4 (more active)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Mastectomy versus partial mastectomy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Axillary lymph node dissection versus sentinel node biopsy
Number of subjects: 220

Group type: COMPARATOR
Intervention: Preoperative physical activity (inactive vs more active)
Number of subjects: 220
Study: 26770032

Group type: EXPERIMENTAL
Intervention: Live attenuated zoster vaccine (ZOSTAVAX™, Merck & Co., Inc.)
Number of subjects: 180
Study: 26770070

Group type: EXPERIMENTAL
Intervention: Person-centred information intervention consisting of four sessions with children's nurses trained in the intervention method.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 26770827

Group type: EXPERIMENTAL
Intervention: Tailored training based on motivational interviewing (MI) techniques
Number of subjects: 45

Group type: COMPARATOR
Intervention: Pre-training measurements
Number of subjects: 45

Group type: COMPARATOR
Intervention: Post-training measurements
Number of subjects: 45
Study: 26771213

Group type: EXPERIMENTAL
Intervention: Nonsynonymous variant rs181206 in IL27
Number of subjects: 12025

Group type: EXPERIMENTAL
Intervention: rs16969968 in CHRNA5
Number of subjects: 12025

Group type: EXPERIMENTAL
Intervention: AGER, MMP3, SERPINA1 variants
Number of subjects: 12025

Group type: EXPERIMENTAL
Intervention: Gene expression datasets
Number of subjects: 12025
Study: 26771550

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 2
Study: 26771572

Group type: EXPERIMENTAL
Intervention: Citalopram (Celexa)
Number of subjects: 0
Study: 26771742

Group type: EXPERIMENTAL
Intervention: Moderate exercise session
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Vigorous exercise session
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control session
Number of subjects: 24
Study: 26771810

Group type: EXPERIMENTAL
Intervention: Carfilzomib (Cfz)
Number of subjects: 62
Study: 26772390

Group type: EXPERIMENTAL
Intervention: Enhanced syphilis screening intervention with standing orders for syphilis serological testing during HIV viral load testing every 3-6 months
Number of subjects: 3100

Group type: COMPARATOR
Intervention: Current provider-initiated syphilis testing practice
Number of subjects: 3100
Study: 26772443

Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the coronary artery (CA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the renal artery (RA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the left superficial femoral artery (SFA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Collateral flow index (CFI) in the left subclavian artery (SCA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation between CA and SFA CFI
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation between left SFA and left SCA CFI
Number of subjects: 100
Study: 26772734

Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day on a 4-week-on, 2-week-off schedule)
Number of subjects: 230
Study: 26772801

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for primary analysis
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for recruitment
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for eligibility
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for setting
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for follow-up
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for primary outcome
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for organization
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for flexibility of intervention delivery
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: PRECIS-2 criteria rating for flexibility of intervention adherence
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Interrater agreement for four trials
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Intraclass correlation coefficient for ratings
Number of subjects: 5
Study: 26772812

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m², 60 min, d 1) and oxaliplatin (80 mg/m², 120 min, d 2) in 21-day cycles for up to 8 cycles
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Docetaxel and oxaliplatin
Number of subjects: 44
Study: 26773458

Group type: EXPERIMENTAL
Intervention: Network-informed clustering of blood gene expression
Number of subjects: 229
Study: 26773712

Group type: EXPERIMENTAL
Intervention: (131) I-MIBG therapy at a dose of 0.67 GBq (18 mCi)/kg/dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rolling lead shields and radiation safety procedures
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Thyroid bioassay scans on medical personnel
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Contamination surveys
Number of subjects: 10
Study: 26774073

Group type: EXPERIMENTAL
Intervention: High neck circumference (NC) in males
Number of subjects: 116

Group type: COMPARATOR
Intervention: Low neck circumference (NC) in males
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Combined use of NC and BMI percentile
Number of subjects: 116

Group type: COMPARATOR
Intervention: BMI percentile alone
Number of subjects: 116
Study: 26774243

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Artesunate plus mefloquine
Number of subjects: 241

Group type: COMPARATOR
Intervention: Single low-dose primaquine
Number of subjects: 241
Study: 26774555

Group type: EXPERIMENTAL
Intervention: Panobinostat 20 mg orally 3 times weekly with letrozole 2.5 mg daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Panobinostat 30 mg orally 3 times weekly with letrozole 2.5 mg daily
Number of subjects: 12
Study: 26774947

Group type: EXPERIMENTAL
Intervention: Weekday adherence
Number of subjects: 255

Group type: COMPARATOR
Intervention: Weekend adherence
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Binge drinking at baseline
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Time on study
Number of subjects: 255
Study: 26775292

Group type: EXPERIMENTAL
Intervention: BioQC testing at 20 W and 70 W
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Composite z-score analysis
Number of subjects: 129
Study: 26777085

Group type: EXPERIMENTAL
Intervention: Intraduodenal levodopa-carbidopa intestinal gel (LCIG) infusion
Number of subjects: 15
Study: 26777228

Group type: EXPERIMENTAL
Intervention: MRI-TULSA treatment
Number of subjects: 30
Study: 26777916

Group type: EXPERIMENTAL
Intervention: Presence of a genetic alteration
Number of subjects: 17664

Group type: COMPARATOR
Intervention: Absence of a genetic alteration
Number of subjects: 17664
Study: 26778344

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26778412

Group type: EXPERIMENTAL
Intervention: ABT-530 with paritaprevir/ritonavir and ribavirin
Number of subjects: 10
Study: 26778949

Group type: EXPERIMENTAL
Intervention: Post-prandial state (after lunch)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pre-prandial state (before lunch)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sucrose gustatory stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Hunger sensation, wanting, liking, and perception of solution's intensity
Number of subjects: 15
Study: 26780395

Group type: EXPERIMENTAL
Intervention: Zinc sulfate (2 capsules of 220 mg each per day for 3 months)
Number of subjects: 60
Study: 26780484

Group type: EXPERIMENTAL
Intervention: Tabalumab (BAFF inhibitor) 240-mg SC at Week 0 followed by 120-mg SC monthly for 5 additional months.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tabalumab (BAFF inhibitor)
Number of subjects: 18
Study: 26780948

Group type: EXPERIMENTAL
Intervention: SMART program
Number of subjects: 3722

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3722
Study: 26781262

Group type: EXPERIMENTAL
Intervention: 6-arm mesh with titanium coating (TILOOP(®) Total 6)
Number of subjects: 289
Study: 26781431

Group type: EXPERIMENTAL
Intervention: Bone mineral density by dual-energy X-ray absorptiometry (DXA) at forearm (FA)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Bone mineral density by dual-energy X-ray absorptiometry (DXA) at femoral neck
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Bone mineral density by dual-energy X-ray absorptiometry (DXA) at lumbar spine
Number of subjects: 89

Group type: COMPARATOR
Intervention: Speed-of-sound (SOS) ultrasonography at forearm (FA)
Number of subjects: 89
Study: 26781548

Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (3.5 h clamp period)
Number of subjects: 24
Study: 26781724

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 1.0 mg plus Tenofovir (TDF) 300 mg combination therapy for 48 weeks
Number of subjects: 64
Study: 26781785

Group type: EXPERIMENTAL
Intervention: Ultrasound7 (US7)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Ultrasound12 (US12)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Infliximab treatment
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DAS28
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: GS + PD
Number of subjects: 82
Study: 26781817

Group type: EXPERIMENTAL
Intervention: High BCAA content diet (14.0±0.6 g valine, 13.8±0.5 g isoleucine, 27.1±1.0 g leucine)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Low BCAA content diet (1.5±0.1 g valine, 4.5±0.9 g isoleucine, 2.1±0.2 g leucine)
Number of subjects: 5
Study: 26782632

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin-resistant Escherichia coli (CipREc) isolates
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: O25b-ST131 lineage CipREc isolates
Number of subjects: 227
Study: 26782796

Group type: EXPERIMENTAL
Intervention: Nursery songs intervention; details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details on intervention not specified.
Number of subjects: 0
Study: 26782971

Group type: EXPERIMENTAL
Intervention: UMEC 125 μg once daily
Number of subjects: 153
Study: 26783523

Group type: EXPERIMENTAL
Intervention: Atlas vertebrae realignment intervention
Number of subjects: 11
Study: 26783591

Group type: EXPERIMENTAL
Intervention: Participation in psychological research
Number of subjects: 0
Study: 26784028

Group type: EXPERIMENTAL
Intervention: Synthetic thyroid hormone (levothyroxine)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroid state (after treatment)
Number of subjects: 10
Study: 26784138

Group type: EXPERIMENTAL
Intervention: Midostaurin 50 mg bid and escalating doses of bortezomib (1 to 1.3 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midostaurin and bortezomib following chemotherapy with mitoxantrone, etoposide, cytarabine (MEC)
Number of subjects: 0
Study: 26784704

Group type: EXPERIMENTAL
Intervention: Clozapine maintenance therapy (dosages ranging from 50 to 900 mg, median dosage of 500 mg)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 131
Study: 26784946

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 68
Study: 26785287

Group type: EXPERIMENTAL
Intervention: CC-486 (oral azacitidine) maintenance therapy (300 mg/day for 14 days of 28-day treatment cycles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26785742

Group type: EXPERIMENTAL
Intervention: Digital quantification of B lymphocytes using anti-CD20 antibodies and image analysis.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Digital quantification of T lymphocytes using anti-CD3 antibodies and image analysis.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Digital method for quantifying B cells.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: B-cell proportion in biopsies with Chisholm grades I-II vs III-IV.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: B-cell proportion across Tarpley's classes.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation of B-cell proportion with clinical and biological activity markers.
Number of subjects: 62
Study: 26785798

Group type: EXPERIMENTAL
Intervention: Health anxiety (hypochondriasis)
Number of subjects: 194
Study: 26786685

Group type: EXPERIMENTAL
Intervention: Endoscopic mucosal resection (EMR) for SSA/Ps
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR) for adenomas
Number of subjects: 2000
Study: 26787251

Group type: EXPERIMENTAL
Intervention: ERSIAS anaesthesia protocol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard anaesthetic care (Control)
Number of subjects: 24
Study: 26787381

Group type: EXPERIMENTAL
Intervention: Cognitive developmental quotients in children with rapidly progressing MPS IIIA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cognitive developmental quotients in children with slowly progressing MPS IIIA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Liver and spleen volumes
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid and urine heparin sulfate levels
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Developmental quotient and cortical gray matter volume
Number of subjects: 25
Study: 26787437

Group type: EXPERIMENTAL
Intervention: Left ventricular endocardial pacing (LVEP)
Number of subjects: 138
Study: 26787795

Group type: EXPERIMENTAL
Intervention: Intraoperative transfusion of packed red blood cells (pRBC)
Number of subjects: 5803
Study: 26787832

Group type: EXPERIMENTAL
Intervention: Recombinant hemagglutinin-based vaccine
Number of subjects: 0
Study: 26788114

Group type: EXPERIMENTAL
Intervention: Whole-grain group (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study: 26788345

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 1200 mg
Number of subjects: 671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 671
Study: 26790007

Group type: EXPERIMENTAL
Intervention: Early loading of splinted OsseoSpeed(™) TX implants
Number of subjects: 45
Study: 26790369

Group type: EXPERIMENTAL
Intervention: Ex vivo costimulatory blockade with belatacept during mixed lymphocyte culture
Number of subjects: 0
Study: 26790480

Group type: COMPARATOR
Intervention: AAV2 neutralizing antibodies (NAbs)
Number of subjects: 42

Group type: COMPARATOR
Intervention: AAV8 neutralizing antibodies (NAbs)
Number of subjects: 42

Group type: COMPARATOR
Intervention: AAV9 neutralizing antibodies (NAbs)
Number of subjects: 42

Group type: COMPARATOR
Intervention: NAbs in patients older than 18 years or those who had received solid organ transplantation
Number of subjects: 42

Group type: COMPARATOR
Intervention: mut(0) patients who had not been transplanted
Number of subjects: 42
Study: 26791079

Group type: EXPERIMENTAL
Intervention: Diabetes camp attendance
Number of subjects: 32
Study: 26791256

Group type: EXPERIMENTAL
Intervention: Oncogramme
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Oncogramme (supplementary analysis)
Number of subjects: 19
Study: 26792544

Group type: EXPERIMENTAL
Intervention: F/B-EVAR
Number of subjects: 354
Study: 26792613

Group type: EXPERIMENTAL
Intervention: Surgical shoes
Number of subjects: 42

Group type: COMPARATOR
Intervention: Preoperative condition (control run)
Number of subjects: 42
Study: 26793344

Group type: EXPERIMENTAL
Intervention: CT-guided biopsy
Number of subjects: 132

Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: EGFR mutation testing
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 132
Study: 26793618

Group type: EXPERIMENTAL
Intervention: PC + D (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks, Dalotuzumab at 10 mg/kg IV weekly on days 1, 8, and 15 of every 3-week cycle)
Number of subjects: 26

Group type: COMPARATOR
Intervention: PC (Pemetrexed at 500 mg/m² and Cisplatin at 75 mg/m² IV every 3 weeks)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PC + D
Number of subjects: 26

Group type: COMPARATOR
Intervention: PC
Number of subjects: 26
Study: 26793976

Group type: EXPERIMENTAL
Intervention: 100 mg oral ART daily for 4 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 150 mg oral ART daily for 4 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 200 mg oral ART daily for 4 weeks
Number of subjects: 23
Study: 26793974

Group type: EXPERIMENTAL
Intervention: Enzalutamide 160 mg/day (phase II)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Enzalutamide (multiple doses in phase I)
Number of subjects: 47
Study: 26794905

Group type: EXPERIMENTAL
Intervention: Twice daily dosing of celgosivir starting on day 0
Number of subjects: 0

Group type: COMPARATOR
Intervention: Twice daily dosing of celgosivir starting on day 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four-times daily treatment of celgosivir
Number of subjects: 0
Study: 26795217

Group type: EXPERIMENTAL
Intervention: Low vitamin A concentration
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Low vitamin C concentration
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Low vitamin E concentration
Number of subjects: 189
Study: 26795447

Group type: EXPERIMENTAL
Intervention: Web- and mobile-based The-Optimal-Lymph-Flow intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Web- and mobile-based Arm Precaution program
Number of subjects: 120
Study: 26795844

Group type: EXPERIMENTAL
Intervention: 10 μg/kg palonosetron
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: 20 μg/kg palonosetron
Number of subjects: 502

Group type: COMPARATOR
Intervention: 3×150 μg/kg ondansetron
Number of subjects: 502
Study: 26796197

Group type: EXPERIMENTAL
Intervention: Symmetrical concentric pmVSD occluder
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Asymmetrical concentric pmVSD occluder
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Transcatheter closure of pmVSDs using modified double-disk occluders
Number of subjects: 337
Study: 26796290

Group type: EXPERIMENTAL
Intervention: Aortic curvature measurement over the juxtarenal aortic neck, aneurysm sac, and terminal aorta.
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Aortic neck calcification measurement.
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Aortic neck angulation measurement.
Number of subjects: 143
Study: 26796390

Group type: EXPERIMENTAL
Intervention: 1-stage percutaneous coronary intervention (1S-PCI)
Number of subjects: 584

Group type: COMPARATOR
Intervention: multistage percutaneous coronary intervention (MS-PCI)
Number of subjects: 584
Study: 26796402

Group type: EXPERIMENTAL
Intervention: P-Selectin Antagonist Inclacumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26796806

Group type: EXPERIMENTAL
Intervention: Internal mammary sentinel lymph node biopsy (IM-SLNB)
Number of subjects: 349
Study: 26796810

Group type: EXPERIMENTAL
Intervention: Single subcutaneous injection of 100 μg/kg pegylated filgrastim
Number of subjects: 53

Group type: COMPARATOR
Intervention: Daily subcutaneous injections of 5 μg/kg filgrastim
Number of subjects: 53
Study: 26796885

Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 82
Study: 26797207

Group type: EXPERIMENTAL
Intervention: Daily oral co-formulated tenofovir/emtricitabine (PrEP)
Number of subjects: 0